Abrocitinib for children with eczema: long-term study
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 6 to 12 years old and weigh at least 33 pounds (15 kg).
- You have had moderate to severe eczema for at least 6 months that covers at least 10% of your body.
- Creams or ointments prescribed by your doctor have not worked well enough.
- You have not used a JAK inhibitor (like abrocitinib) before.
- You do not have serious infections, weakened immune system, or certain blood, kidney, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This study tests whether gradually lowering the dose of abrocitinib can keep your eczema under control while reducing side effects. It is for people with moderate-to-severe eczema who have already been on abrocitinib 200 mg daily for at least 3 months and whose skin is currently well controlled.
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.